| human | Q5 |
| P496 | ORCID iD | 0000-0001-8001-6544 |
| P10897 | ORKG ID | R139252 |
| P1153 | Scopus author ID | 53982707900 |
| P69 | educated at | University College London | Q193196 |
| University of Reading | Q1432632 | ||
| P108 | employer | London School of Hygiene & Tropical Medicine | Q1126189 |
| P735 | given name | Daniel | Q14516546 |
| Daniel | Q14516546 | ||
| P106 | occupation | researcher | Q1650915 |
| P5008 | on focus list of Wikimedia project | WikiProject COVID-19 | Q87748614 |
| P21 | sex or gender | male | Q6581097 |
| Q61192511 | Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa |
| Q95605150 | COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis |
| Q41219108 | Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study |
| Q51070641 | Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? |
| Q34260569 | HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective |
| Q39485675 | Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients |
| Q34387456 | Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults |
| Q41332840 | Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? |
| Q40482468 | Hepatitis C virus (HCV) RNA profiles among chronic HIV/HCV-coinfected individuals in ESPRIT; spontaneous HCV RNA clearance observed in nine individuals. |
| Q42982110 | Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients |
| Q54352996 | Hepatitis delta in HIV-infected individuals in Europe. |
| Q56911375 | High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study) |
| Q124838604 | Identifying Care Home Residents in Electronic Health Records - An OpenSAFELY Short Data Report |
| Q42230942 | Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis |
| Q41336688 | Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals |
| Q42240180 | Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe |
| Q63379735 | Point of care HbA1c level for diabetes mellitus management and its accuracy among tuberculosis patients: a study in four countries |
| Q56931078 | Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial |
| Q63379734 | Risk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated tuberculosis in sub-Saharan Africa: Derivation and external validation cohort study |
| Q43456031 | Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe |
| Q42990589 | Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy |
| Q41967770 | TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality |
| Q33648600 | Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. |
| Q50119032 | Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study |
| Q90459224 | Where are patients missed in the tuberculosis diagnostic cascade? A prospective cohort study in Ghana |
Search more.